ArticleJHEP reports : innovation in hepatology2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.
Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- From Cysts to Metabolism: Trading Metaphors in Medical Language for the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Shifts.Journal of evaluation in clinical practice · 2026Article
- Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.The Lancet regional health. Europe · 2026Review
- Association of physical activity and sedentary time with risk of non-alcoholic fatty liver disease in adults with and without diabetes mellitus.Endocrine journal · 2026Article
- HEALTH-RELATED QUALITY OF LIFE IN CHRONIC LIVER DISEASE: CLINICAL BURDEN, DETERMINANTS, AND IMPLICATIONS FOR PATIENT-CENTERED CARE.Arquivos de gastroenterologia · 2026Review
- A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.Diabetes, obesity & metabolism · 2025Review
- Fatigue in Metabolic Dysfunction-Associated Steatotic Liver Disease: Links to Muscle Function, Hypoxia, and Hypertension.Healthcare (Basel, Switzerland) · 2025Article
- Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD.JHEP reports : innovation in hepatology · 2025Article
- The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Journal of clinical medicine · 2025Article
- The importance of patient engagement in the multimodal treatment of MASLD.Communications medicine · 2025Review
- Metabolic dysfunction-associated steatotic liver disease in adults.Nature reviews. Disease primers · 2025Review
- Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH).JHEP reports : innovation in hepatology · 2025Article
- Curcumin and Its Derivatives in Hepatology: Therapeutic Potential and Advances in Nanoparticle Formulations.Cancers · 2025Review
- The association between the dietary index for gut microbiota and metabolic dysfunction-associated fatty liver disease: a cross-sectional study.Diabetology & metabolic syndrome · 2025Article
- Transcriptome-Wide Association Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Identifies Relevant Gene Signatures.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Review
- Stigma in steatotic liver disease: A survey of patients from Saudi Arabia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
57 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) face a multifaceted disease burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the burden of liver disease in patients with NAFLD and the relationship between experience of stigma and HRQL. Methods: Members of the Global NASH Council created a survey about disease burden in NAFLD. Participants completed a 35-item questionnaire to assess liver disease burden (LDB) (seven domains), the 36-item CLDQ-NASH (six domains) survey to assess HRQL and reported their experience with stigmatization and discrimination. Results: A total of 2,117 patients with NAFLD from 24 countries completed the LDB survey (48% Middle East and North Africa, 18% Europe, 16% USA, 18% Asia) and 778 competed CLDQ-NASH. Of the study group, 9% reported stigma due to NAFLD and 26% due to obesity. Participants who reported stigmatization due to NAFLD had substantially lower CLDQ-NASH scores (all Conclusions: Stigmatization of patients with NAFLD, whether it is caused by obesity or NAFLD, is strongly and independently associated with a substantial impairment of their HRQL. Self-blame is an important part of disease burden among patients with NAFLD. Impact and implications: Patients with nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), may experience impaired health-related quality of life and stigmatization. Using a specifically designed survey, we found that stigmatization of patients with NAFLD, whether it is caused by obesity or the liver disease
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.